Gastric Cancer

, Volume 10, Issue 4, pp 221–227

The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab

Authors

  • Francesca Di Fabio
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Carmine Pinto
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Fabiola L. Rojas Llimpe
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Stefano Fanti
    • Nuclear Medicine UnitS. Orsola-Malpighi Hospital
  • Paolo Castellucci
    • Nuclear Medicine UnitS. Orsola-Malpighi Hospital
  • Ciro Longobardi
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Vita Mutri
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Chiara Funaioli
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Francesca Sperandi
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Stefania Giaquinta
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
  • Andrea A. Martoni
    • Medical Oncology UnitS. Orsola-Malpighi Hospital
Original article

DOI: 10.1007/s10120-007-0438-3

Cite this article as:
Fabio, F., Pinto, C., Rojas Llimpe, F. et al. Gastric Cancer (2007) 10: 221. doi:10.1007/s10120-007-0438-3

Abstract

Background

The aim of the study was to evaluate whether the therapy-induced reduction of the 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) maximum standardized uptake value in patients with advanced gastric adenocarcinoma treated with chemotherapy plus cetuximab could predict the objective response and outcome early during the treatment.

Methods

The study was performed as a part of a phase II trial evaluating cetuximab plus the leucovorin/5-fluorouracil/irinotecan (FOLFIRI) regimen. The objective response was evaluated according to the response evaluation criteria in solid tumors (RECIST) every 6 weeks. The early metabolic response evaluated by 18F-FDG-PET was assessed according to our own evaluated cutoff value (<35%) after receiver operating characteristic (ROC) analysis.

Results

Twenty of 22 patients had positive baseline 18F-FDG-PET. The best RECIST response was: complete response (CR), 3; partial response (PR), 9; stable disease (SD), 8. Twelve patients (60%) were classified as metabolic responders and 8 (40%) as nonresponders. At the median follow-up time of 11 months, median time to disease progression (TTP) and overall survival (OS) for early metabolic responders versus nonresponders were 11 versus 5 months (P = 0.0016) and 16 versus 6 months (P = 0.1493), respectively.

Conclusion

The early metabolic response evaluated by 18F-FDG-PET predicted the clinical outcome in this series of patients with advanced gastric cancer treated with chemotherapy plus cetuximab.

Key words

PETAdvanced gastric adenocarcinomaCetuximab
Download to read the full article text

Copyright information

© International and Japanese Gastric Cancer Association 2007